Inventing New Endpoints with Richard Nkulikiyinka

Transformation in Trials

Join us in a fascinating conversation with our special guests, Richard Nkulikiyinka, as we unravel how endpoints in trials are transforming and the significant role they play in determining trial efficiency. We also delve into innovations in oncology endpoints and discuss the challenges and opportunities in cardiovascular trials. Tune in as we explore the use of composite endpoints in heart failure trials and exciting functional endpoints that are potentially leading the way for approval studies.
We took a deep dive into the critical impacts of trial design and data collection on entire trial enterprises, emphasizing the importance of prospective validation. Richard shared intriguing insights about the changing landscape of trial design and its ripple effect on the industry. He gave an in-depth analysis of sodium-glucose co-transporter inhibitors and the revolutionary changes they brought to the standard of care through a series of trials. You wouldn't want to miss their take on the advantages of umbrella and basket trials and the essential role collaboration plays for their success.
In this riveting discussion, Richard also illuminated the transformative power of innovation and collaboration in clinical trials. We delved into the thrilling potential of cross-company collaboration in investigating the same patient population and the possible role of impartial brokers. Richard also sheds light on how AI and technological advancements could enhance clinical trial outcomes. Listen as they dissect the potential of AI in imaging, its role in streamlining assessment processes, offering real-time feedback, and reducing the burden on specialists. As we wrapped up, we examined how machine learning could make clinical trials more cost-effective by automating the adjudication of events in cardiovascular trials. This enlightening conversation is a treasure trove of insights into the dynamic world of clinical trials.

________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page